As we observed that LDLr deficiency did not affect EAE disease progression, we further explored the inverse, whether reducing circulating cholesterol would attenuate the disease as described for statin treatment. The gene discussed is LDLR; the disease is hyperinsulinemic hypoglycemia, familial, 4.